BioPharmSignal logoBioPharmSignal

Biotech News

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

IceCure Medical (ICCM)IceCure MedicalEarnings

ICCM (ICCM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is iccm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ICCMIceCure Medical2026-05-12 12:30 EST

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

GERNGeron2026-05-06 11:00 EST

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

TMCITreace Medical Concepts2026-05-08 11:05 EST

Treace Medical Concepts Reports First Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

ARGXArgenx2026-05-07 05:00 EST

argenx Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

IceCure Medical

IceCure Medical is a medical device company focused on minimally invasive tumor ablation and cryoablation systems. Its platform is aimed at treating tumors through image-guided procedures.

Recent company news

ICCMIceCure Medical2026-07-27 12:32 EST

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

ICCMIceCure Medical2026-07-06 12:11 EST

IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

ICCMIceCure Medical2026-06-25 12:12 EST

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

ICCMIceCure Medical2026-06-23 12:10 EST

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

Stock data

Close
2.88 USD
Market cap
11.29M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States